Nicholas Investment Partners LP Invests $1.62 Million in Olema Pharmaceuticals, Inc. $OLMA

Nicholas Investment Partners LP bought a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 64,757 shares of the company’s stock, valued at approximately $1,619,000. Nicholas Investment Partners LP owned 0.09% of Olema Pharmaceuticals at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Paradigm Biocapital Advisors LP increased its stake in shares of Olema Pharmaceuticals by 0.4% during the third quarter. Paradigm Biocapital Advisors LP now owns 6,794,172 shares of the company’s stock worth $66,515,000 after purchasing an additional 30,000 shares during the period. Vanguard Group Inc. increased its stake in shares of Olema Pharmaceuticals by 11.4% during the fourth quarter. Vanguard Group Inc. now owns 3,561,355 shares of the company’s stock worth $89,034,000 after purchasing an additional 364,035 shares during the period. Deep Track Capital LP increased its stake in shares of Olema Pharmaceuticals by 0.8% during the third quarter. Deep Track Capital LP now owns 3,470,172 shares of the company’s stock worth $33,973,000 after purchasing an additional 27,339 shares during the period. Siren L.L.C. bought a new position in shares of Olema Pharmaceuticals during the fourth quarter worth approximately $82,518,000. Finally, State Street Corp increased its stake in shares of Olema Pharmaceuticals by 72.3% during the fourth quarter. State Street Corp now owns 1,884,399 shares of the company’s stock worth $47,110,000 after purchasing an additional 790,825 shares during the period. Institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Price Performance

Olema Pharmaceuticals stock opened at $9.87 on Friday. The stock’s fifty day moving average price is $13.96 and its two-hundred day moving average price is $20.57. Olema Pharmaceuticals, Inc. has a one year low of $3.89 and a one year high of $36.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. The firm has a market cap of $862.14 million, a PE ratio of -4.89 and a beta of 1.98.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.52). As a group, research analysts expect that Olema Pharmaceuticals, Inc. will post -2.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OLMA has been the topic of a number of recent research reports. Jefferies Financial Group initiated coverage on Olema Pharmaceuticals in a research note on Thursday, March 19th. They set a “buy” rating and a $40.00 price objective on the stock. Guggenheim lowered their price objective on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Wall Street Zen upgraded Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, April 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Tuesday, April 21st. Finally, TD Cowen restated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Monday, March 9th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Olema Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $44.10.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.